
Oliver SchĶffski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12059365/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 2022, 86, 1116-1119.	1.2	11
2	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. JAMA Dermatology, 2021, 157, 1066.	4.1	24
3	Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 — A ten-year overview. Epilepsy and Behavior, 2018, 83, 28-35.	1.7	57
4	Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Epilepsy and Behavior, 2016, 64, 75-82.	1.7	26
5	Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial. BMC Family Practice, 2016, 17, 49.	2.9	14
6	Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list. BMC Health Services Research, 2016, 16, 109.	2.2	14
7	Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project. Oncology, 2015, 88, 103-121.	1.9	9
8	Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiology and Drug Safety, 2015, 24, 176-186.	1.9	55
9	Palliative treatment of colorectal cancer in Germany: cost of care and quality of life. European Journal of Health Economics, 2013, 14, 629-638.	2.8	12
10	Effects of pay for performance in health care: A systematic review of systematic reviews. Health Policy, 2013, 110, 115-130.	3.0	405
11	Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults. Journal of Neurology, 2012, 259, 2376-2384.	3.6	116
12	Economic evaluation of pay-for-performance in health care: a systematic review. European Journal of Health Economics, 2012, 13, 755-767.	2.8	82
13	Bewertung der Einsparpotenziale in der Arzneimitteltherapie durch Dosisanpassung an die Polymorphismen im Cytochrom P450. PharmacoEconomics - German Research Articles, 2012, 10, 69-85.	0.1	1
14	Costs of acute stroke care on regular neurological wards: A comparison with stroke unit setting. Health Policy, 2007, 81, 339-349.	3.0	37
15	Resource Utilization and Costs of Stroke Unit Care in Germany. Value in Health, 2004, 7, 144-152.	0.3	67
16	What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy, 1998, 44, 253-260.	3.0	40
17	Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany. Pharmacoeconomics, 1996, 10, 37-47.	3.3	36